Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells’ vulnerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with cancer. The Company’s robust, internally developed, clinical pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945, a potentially best in class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1.